Details:
European Commission has granted the marketing authorization for Trimbow inhalation powder delivered through NEXThaler (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) for treatment of moderate to severe COPD.
Lead Product(s): Beclomethasone Dipropionate,Formoterol Fumarate,Glycopyrronium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Trimbow
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2021
Details:
Trimbow is the first extrafine formulation fixed triple combination therapy in a single inhaler to be approved for use in appropriate asthma patients. This follows the 2017 approval of this therapeutic option for the treatment of appropriate moderate to severe COPD patients.
Lead Product(s): Beclomethasone Dipropionate,Formoterol Fumarate,Glycopyrronium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Trimbow
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2021
Details:
Chiesi Farmaceutici and Bayer have entered into a co-promotion agreement for Clenil® and Foster® in China, two products of Chiesi Group’s established portfolio in the respiratory therapeutic area.
Lead Product(s): Beclomethasone Dipropionate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Clenil
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 13, 2020